Research outputs
2025
Ribociclib with an aromatase inhibitor for adjuvant treatment of hormone receptor-positive, HER2-negative early breast cancer [ID6153]: A Single Technology Appraisal
Bresnahan, R., Harvey, R., Stainthorpe, A., Bryning, S., Beale, S., Boland, A., . . . Malik, Z. (2025). Ribociclib with an aromatase inhibitor for adjuvant treatment of hormone receptor-positive, HER2-negative early breast cancer [ID6153]: A Single Technology Appraisal. Retrieved from https://www.nice.org.uk/guidance/ta1086/documents/committee-papers-2
2024
Durvalumab with etoposide and platinum-based chemotherapy for untreated extensive-stage small cell lung cancer (Review of TA662) [ID6404]
Fleeman, N., Bryning, S., Beale, S., Boland, A., Dundar, Y., Marsden, A., & Green, J. (2024). Durvalumab with etoposide and platinum-based chemotherapy for untreated extensive-stage small cell lung cancer (Review of TA662) [ID6404]. Retrieved from https://www.nice.org.uk/guidance/TA1041
Nivolumab-relatlimab for untreated unresectable or metastatic melanoma [ID1688]: A Single Technology Appraisal.
Bresnahan, R., Fleeman, N., Stainthorpe, A., Bryning, S., Nevitt, S., Mahon, J., . . . Danson, S. (2024). Nivolumab-relatlimab for untreated unresectable or metastatic melanoma [ID1688]: A Single Technology Appraisal.. Retrieved from https://www.nice.org.uk/guidance/ta950/documents/committee-papers
2023
Momelotinib for treating disease-related splenomegaly or symptoms in adults with myelofibrosis [ID6141]: A Single Technology Appraisal
Fleeman, N., Bresnahan, R., Mahon, J., Bryning, S., Beale, S., Boland, A., . . . Butt, N. (2023). Momelotinib for treating disease-related splenomegaly or symptoms in adults with myelofibrosis [ID6141]: A Single Technology Appraisal. Retrieved from https://www.nice.org.uk/guidance/ta957/evidence/committee-papers-pdf-13363268509
Durvalumab with gemcitabine and cisplatin for treating unresectable or advanced biliary tract cancer [ID4031]
Greenhalgh, J., Mahon, J., Bryning, S., Chaplin, M., Beale, S., Boland, A., . . . Basu, B. (2023). Durvalumab with gemcitabine and cisplatin for treating unresectable or advanced biliary tract cancer [ID4031]: Durvalumab with gemcitabine and cisplatin for treating unresectable or advanced biliary tract cancer [ID4031]. Retrieved from https://www.nice.org.uk/guidance/gid-ta10920/documents/committee-papers